CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

Main purpose: Using the linezolid dry suspension produced by Shijiazhuang Zhongnuo Pharmaceutical Co., Ltd. of Shijiazhuang Pharmaceutical Group as the test preparation and the linezolid dry suspension produced by Pfizer Service Company BVBA (trade name: Zyvox®) as the reference preparation, the pharmacokinetic behavior of the linezolid dry suspension in healthy subjects was compared according to the relevant provisions of the bioequivalence test, and the bioequivalence of the two preparations was evaluated. Secondary purpose: To evaluate the safety of the linezolid dry suspension test preparation and the reference preparation after a single oral administration on an empty stomach in healthy subjects.

The main purpose of the study is to study the pharmacokinetics of the test preparation upadacitinib extended-release tablets (specification: 15 mg/tablet, produced by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.) and the reference preparation upadacitinib extended-release tablets (Ruifu, specification: 15 mg/tablet; produced by AbbVie Ireland NL B.V.) in healthy subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary purpose of the study is to study the safety of the test preparation upadacitinib extended-release tablets 15 mg and the reference preparation Ruifu 15 mg in healthy subjects.